{"Clinical Trial ID": "NCT00030823", "Intervention": ["INTERVENTION 1:", "Vaccine", "Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously at weeks 1, 2, 3, 7 and 19."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Diagnosis of breast cancer at high risk of recurrence, defined by one of the following criteria:", "Stage IV free of any known disease after eradication by surgery, radiotherapy or chemotherapy", "- May or may not have high levels of CA 15-3 or ECA", "Stage I, II or III previously treated with adjuvant chemotherapy and clinically free from identifiable disease, but show an increase in CA 15-3 or CEA levels", "The increase in CA 15-3 and CEA defined as a previous normal level increased on 2 consecutive occasions at least 2 weeks apart", "For patients with a significant history of smoking with chronically elevated ACE (less than 15), the ACE should be increased at least 1.5 times the highest chronic value twice consecutively at least 2 weeks apart.", "Stage III and adjuvant treatment completed no more than 24 months ago", "Recurrence in the ipsilateral axil after lumpectomy and/or axillary dissection or modified radical mastectomy", "Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection", "Stage II with at least 4 positive axillary lymph nodes and adjuvant treatment completed 24 months ago", "Stage IV which is stable on hormonal treatment", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age:", "- 18 years and over", "Gender:", "Men or women", "Status of menopause:", "Unspecified", "Status:", "Karnofsky 80-100%", "Life expectancy:", "Unspecified", "Haematopoietic:", "Number of lymphocytes at least 500/mm^3", "WBC at least 3000/mm^3", "Hepatic:", "ASAT not exceeding 1.5 times the upper limit of normal (ULN)", "ALKALINE phosphatase not more than 1.5 times LSN", "- Renal:", "- Creatinine not exceeding 1.5 times ULN", "Cardiovascular disorders:", "No class III or IV cardiac disease from the New York Heart Association clinically significant", "Other:", "Not pregnant", "Negative pregnancy test", "Fertile patients should use effective contraception", "No previous allergy to seafood", "No previous immunodeficiency or known autoimmune disease", "No other active cancer except skin cancer of basal or squamous cells", "THERAPE PRIOR CONCURENT:", "Biological therapy:", "At least 6 weeks after previous immunotherapy", "No previous vaccine with any of the antigens in this study", "- Chemotherapy:", "See Disease Characteristics", "At least 4 weeks since previous chemotherapy", "No concomitant chemotherapy", "Endocrinotherapy:", "See Disease Characteristics", "Radiotherapy:", "See Disease Characteristics", "At least 4 weeks since previous radiation therapy", "No simultaneous radiotherapy", "Surgery:", "See Disease Characteristics", "At least 4 weeks since the previous operation", "\u2022 Concomitant surgery for local recurrence is allowed if the patient remains disease free"], "Results": ["Performance measures:", "Security", "By assessing toxicity and classifying itself after immunization with the multi-purpose vaccine in accordance with the NCI Common Toxicity Criteria 2.0.", "Time limit: 2 years", "Results 1:", "Title of the arm/group: Vaccine", "Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously on weeks 1, 2, 3, 7 and 19.", "Total number of participants analysed: 13", "Type of measurement: Number", "Unit of measurement: participants 13"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/13 (7.69 per cent)", "- SGPT (ALT) 1/13 (7.69%)"]}